SAS, Optum Offer Cloud-Based Health Analytics Platform
The shift from volume- to performance-based payment is propelling life sciences companies to seek concrete data and medical evidence – both to understand patient care and to demonstrate the effectiveness, safety and value of drug therapies.
The shift from volume- to performance-based payment is propelling life sciences companies to seek concrete data and medical evidence – both to understand patient care and to demonstrate the effectiveness, safety and value of drug therapies. To help life sciences clients better manage, analyze and share data, business analytics company SAS is launching a cloud-based, real-world data analytics platform.
The new service features de-identified integrated claims and clinical data about everyday patients receiving health care, including prescriptions and labs – data from the real world, not just trials. For the new platform, Optum, a leading information and technology-enabled health services business and part of United HealthCare, is the first collaborator and will contribute health care expertise, analytics and vast stores of clinical data to the SAS® data warehousing platform.
Read the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
